Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010198077> ?p ?o ?g. }
- W2010198077 endingPage "912" @default.
- W2010198077 startingPage "906" @default.
- W2010198077 abstract "The specific aims of the study were to evaluate the 2-year overall survival (OS) and progression-free survival (PFS), toxicity profile, and best objective response rate in patients with locally advanced, clinically unresectable esophageal cancer receiving cetuximab, cisplatin, irinotecan, and thoracic radiotherapy (TRT) within a multi-institutional cooperative-group setting.Eligible patients (cT4 M0 or medically unresectable, biopsy proven, and noncervical esophageal cancer) were to receive four 21-day cycles of cetuximab 400 mg/m (day 1, cycle 1), cetuximab 250 mg/m (day 8, 15, cycle 1; then days 1, 8, and 15 for subsequent cycles), cisplatin 30 mg/m (days 1 and 8, all cycles), and irinotecan 65 mg/m (days 1 and 8, all cycles). TRT was administered at 1.8 Gy in 28 daily fractions to a total dose of 50.4 Gy, to begin with on day 1 of cycle 3. The primary endpoint was 2-year OS, with an accrual goal of 75 patients with adenocarcinoma.The study was closed because of slow accrual, with 21 eligible patients (11 squamous, 10 adenocarcinoma) enrolled from May 2005 to September 2007. Two-year OS and PFS (95% confidence interval [CI]) were 33.3% (14.6-57.0%) and 23.8% (8.2-47.2%), respectively. Kaplan-Meier estimates of median (95% CI) OS and PFS were 11.2 (6.4-43.6) and 6.4 (3.7-12.0) months, respectively. The overall response rate (95% CI) among 17 evaluable patients was 17.6% (3.8-43.4%), including 6% confirmed complete responders and 12% unconfirmed partial responders. Two deaths resulted from protocol treatment (sudden death and gastrointestinal necrosis). Ten (47.6%) and 6 (28.6%) patients had grade-3 or -4 toxicity, respectively: 52.4% were hematologic, 23.8% had fatigue, 19.0% had nausea, 19.0% had dehydration, and 19.0% had anorexia.Concomitant cetuximab, cisplatin, irinotecan, and TRT were poorly tolerated in the first North American cooperative group trial testing this regimen for locally advanced esophageal cancer as treatment-related mortality approached 10%. Single-institution phase-II cetuximab-based combined modality trials have yielded encouraging results in preliminary analyses. The SWOG GI Committee endorses enrollment to open clinical trials to clarify the therapeutic ratio of cetuximab-based combined modality approaches for esophageal cancer." @default.
- W2010198077 created "2016-06-24" @default.
- W2010198077 creator A5002909505 @default.
- W2010198077 creator A5015065013 @default.
- W2010198077 creator A5028989632 @default.
- W2010198077 creator A5034428260 @default.
- W2010198077 creator A5038266686 @default.
- W2010198077 creator A5055339191 @default.
- W2010198077 creator A5066487010 @default.
- W2010198077 creator A5070973399 @default.
- W2010198077 creator A5087376683 @default.
- W2010198077 creator A5091279526 @default.
- W2010198077 date "2012-05-01" @default.
- W2010198077 modified "2023-10-18" @default.
- W2010198077 title "Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414)" @default.
- W2010198077 cites W1525737532 @default.
- W2010198077 cites W1920900131 @default.
- W2010198077 cites W1964929669 @default.
- W2010198077 cites W1968041240 @default.
- W2010198077 cites W1971557931 @default.
- W2010198077 cites W1977450976 @default.
- W2010198077 cites W1983102735 @default.
- W2010198077 cites W2006038382 @default.
- W2010198077 cites W2009884987 @default.
- W2010198077 cites W2022940390 @default.
- W2010198077 cites W2024114545 @default.
- W2010198077 cites W2024357079 @default.
- W2010198077 cites W2026657556 @default.
- W2010198077 cites W2027185592 @default.
- W2010198077 cites W2030285422 @default.
- W2010198077 cites W2040611894 @default.
- W2010198077 cites W2046481359 @default.
- W2010198077 cites W2049708352 @default.
- W2010198077 cites W2050136440 @default.
- W2010198077 cites W2070448053 @default.
- W2010198077 cites W2080530315 @default.
- W2010198077 cites W2092925950 @default.
- W2010198077 cites W2095632509 @default.
- W2010198077 cites W2100532275 @default.
- W2010198077 cites W2105499277 @default.
- W2010198077 cites W2117907121 @default.
- W2010198077 cites W2127191258 @default.
- W2010198077 cites W2131922643 @default.
- W2010198077 cites W2134142320 @default.
- W2010198077 cites W2144263975 @default.
- W2010198077 cites W2145830863 @default.
- W2010198077 cites W2152452482 @default.
- W2010198077 cites W2155384808 @default.
- W2010198077 cites W2156071539 @default.
- W2010198077 cites W2158896930 @default.
- W2010198077 cites W2160551594 @default.
- W2010198077 cites W2165948908 @default.
- W2010198077 cites W2279052620 @default.
- W2010198077 cites W2333908381 @default.
- W2010198077 doi "https://doi.org/10.1097/jto.0b013e31824c7bed" @default.
- W2010198077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3382003" @default.
- W2010198077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22481235" @default.
- W2010198077 hasPublicationYear "2012" @default.
- W2010198077 type Work @default.
- W2010198077 sameAs 2010198077 @default.
- W2010198077 citedByCount "49" @default.
- W2010198077 countsByYear W20101980772013 @default.
- W2010198077 countsByYear W20101980772014 @default.
- W2010198077 countsByYear W20101980772015 @default.
- W2010198077 countsByYear W20101980772016 @default.
- W2010198077 countsByYear W20101980772017 @default.
- W2010198077 countsByYear W20101980772018 @default.
- W2010198077 countsByYear W20101980772019 @default.
- W2010198077 countsByYear W20101980772020 @default.
- W2010198077 countsByYear W20101980772021 @default.
- W2010198077 countsByYear W20101980772023 @default.
- W2010198077 crossrefType "journal-article" @default.
- W2010198077 hasAuthorship W2010198077A5002909505 @default.
- W2010198077 hasAuthorship W2010198077A5015065013 @default.
- W2010198077 hasAuthorship W2010198077A5028989632 @default.
- W2010198077 hasAuthorship W2010198077A5034428260 @default.
- W2010198077 hasAuthorship W2010198077A5038266686 @default.
- W2010198077 hasAuthorship W2010198077A5055339191 @default.
- W2010198077 hasAuthorship W2010198077A5066487010 @default.
- W2010198077 hasAuthorship W2010198077A5070973399 @default.
- W2010198077 hasAuthorship W2010198077A5087376683 @default.
- W2010198077 hasAuthorship W2010198077A5091279526 @default.
- W2010198077 hasBestOaLocation W20101980771 @default.
- W2010198077 hasConcept C121608353 @default.
- W2010198077 hasConcept C126322002 @default.
- W2010198077 hasConcept C143998085 @default.
- W2010198077 hasConcept C168563851 @default.
- W2010198077 hasConcept C203092338 @default.
- W2010198077 hasConcept C2776694085 @default.
- W2010198077 hasConcept C2778239845 @default.
- W2010198077 hasConcept C2779742542 @default.
- W2010198077 hasConcept C2779998722 @default.
- W2010198077 hasConcept C2780259306 @default.
- W2010198077 hasConcept C2780739268 @default.
- W2010198077 hasConcept C2781182431 @default.
- W2010198077 hasConcept C31760486 @default.
- W2010198077 hasConcept C509974204 @default.
- W2010198077 hasConcept C526805850 @default.